Derek E. Murrell

East Tennessee State University — United States

Medicine · Health Sciences

7h-index122citations19works0.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV/AIDS drug development and treatment(6), Inflammatory mediators and NSAID effects(5), Neuropeptides and Animal Physiology(4), HIV Research and Treatment(3), Biochemical and Molecular Research(3)

Publications19 total

Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Remimazolam
European Journal of Drug Metabolism and Pharmacokinetics·2025· 1 citedOpen Access
Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood
Toxicology Reports·2025Open Access
An Exploratory Pharmacogenetic Pilot Study of Two Reverse Transcriptase Inhibitors, Tenofovir Alafenamide Fumarate and Tenofovir Disoproxil Fumarate
Drugs in R&D·2025· 1 citedOpen Access
Type 2 diabetes: an exploratory genetic association analysis of selected metabolizing enzymes and transporters and effects on cardiovascular and renal biomarkers
Drug Metabolism and Personalized Therapy·2022· 2 cited
HIV Integrase Inhibitor Pharmacogenetics: An Exploratory Study
Clinical Drug Investigation·2019· 7 cited
HIV Integrase Inhibitor Pharmacogenetics and Clinical Outcomes: An Exploratory Association Study
Digital Commons - East Tennessee State University (East Tennessee State University)·2018Open Access
Formulation and in vivo evaluation of aliskiren-loaded poly(lactic-<i>co</i>-glycolic) acid nanoparticles
Toxicology Research and Application·2018· 2 citedOpen Access
Chromatographic methods in HIV medicine: Application to therapeutic drug monitoring
Biomedical Chromatography·2017· 8 cited
Simultaneous Determination of Five Antiretroviral Drugs Plus Cobicistat in Human Plasma Using Strong Cation Mixed-Mode SPE and HPLC-MS/MS
Digital Commons - East Tennessee State University (East Tennessee State University)·2017
Improving Relative Bioavailability of Orally Dosed Aliskiren through Poly(lactic-co-glycolic) Acid Nanoformulation in Rats
Digital Commons - East Tennessee State University (East Tennessee State University)·2017
Assessment of celecoxib poly(lactic-co-glycolic) acid nanoformulation on drug pharmacodynamics and pharmacokinetics in rats.
PubMed·2016· 10 cited
The Effect of Celecoxib Poly(lactic-co-glycolic) Acid Nanoformulation on Renal and Gastrointestinal Outcomes in Rats
2016
Examination of Poly(lactide-co-glycolide) Nanoparticle Formulation on Diclofenac-Associated Renal and Gastrointestinal Effects in Rats
2016
Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections
International Journal of Pharmacy Practice·2016· 26 cited
Celecoxib or diclofenac hepatic status in the presence or absence of rebamipide.
PubMed·2015
Effects of formulation design on niacin therapeutics: mechanism of action, metabolism, and drug delivery
International Journal of Pharmaceutics·2015· 34 cited
Stribild: a review of component characteristics and combination drug efficacy.
PubMed·2015· 12 cited
Histopathology and oxidative stress analysis of concomitant misoprostol and celecoxib administration
Journal of Toxicologic Pathology·2015· 3 citedOpen Access
Exacerbation of Celecoxib-Induced Renal Injury by Concomitant Administration of Misoprostol in Rats
PLoS ONE·2014· 16 citedOpen Access

Frequent Co-authors

Sam Harirforoosh(15), Stacy D. Brown(7), James W. Denham(4), David B. Cluck(3), Peter C. Panus(3), Jonathan P. Moorman(3), Dustin L. Cooper(2), Kesheng Wang(2), Michelle M. Duffourc(2), David S. Roane(1), John B. Bossaer(1), Ronald Carico(1), Christopher M. Conder(1), Victoria Palau(1), Grace E. Campbell(1), Shaun P. Lynch(1), Angela Hanley(1), Kenny W. Bullins(1), Krishna Singh(1), Kelsi O West(1)